BAC arrays, 76
Basaloid carcinoma, molecular and cellular
pathology of, 297
Basic fibroblast growth factor (bFGF)
angiogenicity of, 171
in molecular prognostication, 149
for radiotherapy risk reduction,
631–632
BAY 43-900b (sorafenib), 703–705, 704t,
744, 857t, 858
BAY12-9566, for SCLC, 855, 855t
BB10901, for SCLC, 856
B cells, in inflammation, 174
BCL2 gene, 81
Bcr-Abl, 745
Beam arrangements/aids, for radiotherapy,
555–557, 556f
Beam energy, 556
Beam’s eye view (BEV) tool, 556
BEC-2/BCG, for SCLC, 855t, 856
BEC2 vaccine, 761t, 762
Benzo(a)pyrene, 9
Beryllium, lung cancer from, 35–36
_-carotene
as chemoprevention, 13, 47, 277–278,
278t, 279t
on lung cancer risk, 216
Bevacizumab, 127, 699–700, 700t
in adjuvant setting, 701
on angiogenesis, 175
biomarkers for benefits from, 143
for brain metastases, 702, 702t
for malignant mesothelioma, 955
in neoadjuvant setting, 701–702
for NSCLC
advanced, gender on, 364, 364t
completely resected, 786
recurrent/refractory, plus chemotherapy,
680–681
plus erlotinib, 700–701
plus erlotinib with carboplatin, paclitaxel,
and radiotherapy, 772
plus radiotherapy, 198t, 769
for SCLC, 702–703, 857–858, 857t
squamous cell histology and, 702
bFGF, 123, 125t, 126
Bilobectomy, for NSCLC stage II, 477
Biologic risk factors, 48
Biology. See also specific topics
cancer stem cell (CSC) hypothesis in,
163–168 ( See also Cancer stem
cell [CSC] hypothesis)
microenvironment in, 171–175 ( See also
Microenvironment)
molecular ( See Molecular biology)
molecular prognostication in, 147–157
( See also Molecular
prognostication)
mouse models of lung cancer, 179–186
( See also Mouse models, lung
cancer)
proteomics in, 135–144 ( See also
Proteomics)
of radiotherapy
cell cycle and vascular targets for,
189–200 ( See also under
Radiotherapy)
dose fractionation in, 569–574
( See also Radiotherapy, dose
fractionation in)
timing of, 574–575, 575f
Biomarkers. See also specific biomarkers and
cancers
blood-based, 267
blood-based, for early detection, 267
for chemotherapy
adjuvant, in completely resected
NSCLC, 786–787
for antimitotic drugs, 688
pharmacogenics as, 683–690
( See also Pharmacogenics,
as biomarkers for
chemotherapy)
for platinum resistance, 684–688,
684f–686f, 687t
single gene biomarkers in, 684–688
in early detection and prevention,
219–220
for malignant mesothelioma, 950, 950f
methylation, 266, 786
need for, 778
for platinum resistance, single gene,
684–688
BRCA1, 686–687, 687f, 687t
ERCC1, 684–685, 684f–686f, 687t
p27, 687t
p53, 687t
for platinum resistance, 684–688,
684f–686f, 687t
RRM1 in, 684f–686f, 685–686, 687t
proteomic, 137–138, 137t
discovery approaches for, 138–139, 138f,
139f
for early detection, 140–142, 141f
for radiation sensitivity risk prediction, 627
sputum analysis for, 241
Biopsies, bronchial, 293–294, 293f
Bis(chloromethyl) ether (BCME), lung
cancer from, 10, 11t, 36
Blood-based markers, for early detection,
267. See also Biomarkers
Blood supply, to tumors, 113. See also specific
cancers
BMS-354825 (dasatinib), 745
BNIP3, 125t, 126
Bone metastases, of NSCLC, 332
Bortezomib
for malignant mesothelioma, 955
for SCLC, 856, 856t
Bortezomib-docetaxel, for recurrent/ refractory
NSCLC, 675–676, 675t
Bosutinib (SKI-606), 745
Brachytherapy
ablational, 898
intraoperative
historical background on, 509
plus sublobar resection, for inoperable
cancer, 509–510, 510f
plus limited resection for stage I cancer,
adjuvant, 463
BRAF mutations, 64
Brain metastases
bevacizumab for, 702, 702t
clinical presentation, diagnosis, and
prognosis with, 911, 912t
evaluation of, 503–504, 503t
incidence of, 911
in lung cancer patients, 332
management of, 911–924
corticosteroids in, 911–912
radiosensitizers in, concurrent, 916–917,
917t
radiosurgery boost trials on, 913–915,
914t
surgical, 503–504, 503t
surgical resection in, 913, 913t
for synchronous, solitary brain metastases
from NSCLC, 917–920
anticonvulsants in, 920
with leptomeningeal carcinomatosis,
918–919, 919t
neurocognitive decline etiology in,
919–920
research on, 917–918, 918t
whole-brain radiotherapy in, 912, 912t
postoperative, 915–916, 916t
repeat, 916
in NSCLC
overview of, 837 ( See also Cranial irradiation,
prophylactic, for NSCLC)
risk of, 837–839, 838t
984 INDEX
BRCA1, as predictor for platinum resistance,
686–687, 687f, 687t
Breath, early detection via, 269–271, 270f
Breath-hold methods, for radiotherapy, 555
Bronchial adenoma, 302–305, 971. See
also Atypical adenomatous
hyperplasia (AAH)
Bronchial biopsies, 293–294, 293f
Bronchial carcinoids. See Carcinoid tumors
Bronchial dysplasia. See also Pathology,
molecular and cellular
immunohistochemical changes in,
289–290
preneoplasia genetics in, 290–291, 290f,
291f
Bronchioloalveolar carcinoma (BAC)
as bilateral air space disease, 369, 372f
fine-needle aspiration cytology of, 243–245,
244f
with ground-glass opacities ( See also
Ground-glass opacities [GGO])
intervention for, 469–471
molecular and cellular pathology of,
303–305, 304f
cytology in, 304
histology in, 303–304, 304f
history of, 303
immunohistochemistry in, 305
multiple nodules in, 369, 371f
nonmucinous, 468
Bronchioloalveolar stem cells, in murine
tumorigenesis, 165
Bronchitis, chronic, on lung cancer
incidence, 15
Bronchoalveolar lavage (BAL), 241,
267–268, 268f
Bronchogenic cysts, 968
Bronchopleural fistula, postoperative,
535–537, 536f
Bronchoscope, 241
Bronchoscopy
for diagnosis and evaluation, 417–421
aspiration in, 417
of central airway lesions, 418–419
history of, 417
mediastinal lymph node staging with,
417, 418f
mediastinal node staging with, recent
issues in, 419–421, 419f, 419t
of NSCLC stage II, 475
sampling in, 417
standard and autofluorescence-guided
sampling in, 419
for submillimeter parenchymal lesions,
418
for early detection, 257–262
autofluorescence, 266
in central airways, 257–260
autofluorescence reflectance bronchoscopy,
257–259, 258t, 259f
endobronchial ultrasound, 260, 260f
high-magnification videobronchoscopy,
260
history and development, 257
narrow-band imaging, 260
optical coherence tomography,
259–260, 259f
optical techniques in, 266
in peripheral lung, 260–262
electromagnetic navigation,
261–262, 262t
endobronchial ultrasound, 261, 261t
history, 260–261
multimodality bronchoscopic
diagnosis, 262
history of, 417
rigid
for airway interventions, 894
for airway problems, 896, 896f
for treatment of early lung cancer,
421–422, 421f
virtual, 266
Budesonide, as chemoprevention, 217
B7.1 vaccine (CD80_), 755t, 756t, 757
Bystander cell killing, 569
Bystander vaccines, 753
0 komentar:
Posting Komentar